<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02144090</url>
  </required_header>
  <id_info>
    <org_study_id>O2 Pilot Study</org_study_id>
    <nct_id>NCT02144090</nct_id>
  </id_info>
  <brief_title>Opsens Optowire for Fractional Flow Reserve - The O2 Pilot Study</brief_title>
  <acronym>O2</acronym>
  <official_title>Opsens Optowire for Fractional Flow Reserve - The O2 Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laval University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Opsens Medical</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>International Chair on Interventional Cardiology and Transradial Approach</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Laval University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the usability and safety of the Opsens OptoWire and&#xD;
      Optomonitor in measuring fractional flow reserve (FFR) in patients with coronary artery&#xD;
      disease who are undergoing a coronary angiogram.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fractional flow reserve (FFR) measurement involves determining the ratio between the maximum&#xD;
      achievable blood flow in a diseased coronary artery and the theoretical maximum flow in a&#xD;
      normal coronary artery. An FFR of 1.0 is widely accepted as normal. An FFR value lower than&#xD;
      0.75 - 0.80 is generally considered to be associated with myocardial ischemia (MI).&#xD;
&#xD;
      FFR is easily measured during routine coronary angiography by using a pressure wire to&#xD;
      calculate the ratio between coronary pressure distal to a coronary artery stenosis and aortic&#xD;
      pressure under conditions of maximum myocardial hyperemia. This ratio represents the&#xD;
      potential decrease in coronary flow distal to the coronary stenosis.&#xD;
&#xD;
      Over the past decade, FFR measurement has been increasingly used in cardiac catheterization&#xD;
      laboratories. It provides a quantitative assessment of the functional severity of a coronary&#xD;
      artery stenosis identified during coronary angiography and cardiac catheterization.&#xD;
&#xD;
      Opsens, Inc. has developed a new pressure wire for use in determining FFR in coronary&#xD;
      arteries; the OptoWire. The OptoWire is an instrumented guide wire with a fiber optic&#xD;
      pressure sensor mounted 3.5 cm proximal to the tip. The Optowire measures blood pressure&#xD;
      during diagnostic and/or interventional procedures when used in combination with the&#xD;
      OptoMonitor.&#xD;
&#xD;
      The O2 study is a pilot study which aims to provide preliminary experience in human patients&#xD;
      with coronary artery disease. The study data will also be used as part of design validation.&#xD;
&#xD;
      The O2 study is a prospective single arm study designed to assess the usability,&#xD;
      functionality, and safety of the Optowire and Optomonitor in patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and handling assessment of the Optowire</measure>
    <time_frame>Patients will be followed through removal of the OptoWire from percutaneous insertion site and completion of the cardiac catheterization procedure (expected average &lt;1hr)</time_frame>
    <description>Safely reach and cross a target lesion;&#xD;
perform an FFR measurement using the Optowire and Optomonitor according to the product user guide;&#xD;
disconnect the proximal connector on the OptoWire during the procedure, placing an interventional device (if necessary), and reconnecting the Optowire proximal connector;&#xD;
safely remove the Optowire from the coronary artery.&#xD;
Dedicated questionnaires will be used for such assessment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of FFR values measured with Optowire vs. with FFR guide wire used in standard practice</measure>
    <time_frame>Patients will be followed through removal of the OptoWire from percutaneous insertion site and completion of the cardiac catheterization procedure (expected average &lt;1hr)</time_frame>
    <description>In selected cases, the operator may choose to perform FFR measurements using currently approved FFR wires. Values obtained with standard FFR wires and Optowire may therefore be compared.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Stable Angina</condition>
  <condition>Unstable Angina Pectoris</condition>
  <condition>Chest Pain</condition>
  <condition>Ischemia</condition>
  <arm_group>
    <arm_group_label>Fractional flow reserve</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fractional flow reserve measurement</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Fractional flow reserve measurement</intervention_name>
    <description>Fractional flow reserve measurement</description>
    <arm_group_label>Fractional flow reserve</arm_group_label>
    <other_name>Opsens Optowire and Optomonitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with&#xD;
&#xD;
               -  Stable angina or,&#xD;
&#xD;
               -  Unstable angina pectoris or,&#xD;
&#xD;
               -  Atypical chest pain or no chest pain but with suspected ischemia&#xD;
&#xD;
          -  At least one moderate lesion in native coronary artery thought to produce ischemia&#xD;
&#xD;
          -  Operator and patient agree for procedures&#xD;
&#xD;
          -  Patient (&gt; 18 years) has signed a written informed consent prior to procedure&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Lesions with angiographic 'haziness' or suspected to contain thrombus&#xD;
&#xD;
          -  Post-coronary artery bypass grafting&#xD;
&#xD;
          -  Total occlusion&#xD;
&#xD;
          -  If use of atherectomy device is indicated&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olivier F Bertrand, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>International Chair on Interventional Cardiology and Transradial Approach</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>IUCPQ - Laval Hospital</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <study_first_submitted>May 15, 2014</study_first_submitted>
  <study_first_submitted_qc>May 16, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2014</study_first_posted>
  <last_update_submitted>July 9, 2015</last_update_submitted>
  <last_update_submitted_qc>July 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Laval University</investigator_affiliation>
    <investigator_full_name>Olivier F. Bertrand</investigator_full_name>
    <investigator_title>Study Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Angiography</keyword>
  <keyword>Angioplasty</keyword>
  <keyword>Coronary artery disease</keyword>
  <keyword>Diagnostic</keyword>
  <keyword>Fractional flow reserve</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angina Pectoris</mesh_term>
    <mesh_term>Angina, Stable</mesh_term>
    <mesh_term>Angina, Unstable</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Chest Pain</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

